Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2018 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment.
Martinenaite E, Munir Ahmad S, Hansen M, Met Ö, Westergaard MW, Larsen SK, Klausen TW, Donia M, Svane IM, Andersen MH. Martinenaite E, et al. Oncoimmunology. 2016 Sep 30;5(11):e1238541. doi: 10.1080/2162402X.2016.1238541. eCollection 2016. Oncoimmunology. 2016. PMID: 27999757 Free PMC article.
Tumor cells and tumor-infiltrating macrophages produce the chemokine CCL22, which attracts regulatory T cells (Tregs) into the tumor microenvironment, decreasing anticancer immunity. ...The addition or activation of CCL22
Tumor cells and tumor-infiltrating macrophages produce the chemokine CCL22, which attracts regulatory T
Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice.
Hsu FT, Chen TC, Chuang HY, Chang YF, Hwang JJ. Hsu FT, et al. Oncotarget. 2015 Dec 29;6(42):44134-50. doi: 10.18632/oncotarget.6628. Oncotarget. 2015. PMID: 26683520 Free PMC article.
Ex vivo expansion of CD8+ T-cells has been a hindrance for the success of adoptive T cell transfer in clinic. Currently, preconditioning with chemotherapy is used to modulate the patient immunity before ACT, however, the tumor microenvironmen
Ex vivo expansion of CD8+ T-cells has been a hindrance for the success of adoptive T cell transfer in clinic. Currently …
Glycocalyx-Mimicking Nanoparticles Improve Anti-PD-L1 Cancer Immunotherapy through Reversion of Tumor-Associated Macrophages.
Zhang Y, Wu L, Li Z, Zhang W, Luo F, Chu Y, Chen G. Zhang Y, et al. Biomacromolecules. 2018 Jun 11;19(6):2098-2108. doi: 10.1021/acs.biomac.8b00305. Epub 2018 Apr 16. Biomacromolecules. 2018. PMID: 29634251
Immune checkpoint blockade by anti-PD-L1 monoclonal antibody (αPD-L1) has achieved unprecedented clinical benefits in certain cancers, whereas the therapeutic efficacy is often hindered by immunosuppressive tumor microenvironment mediated by tumor
Immune checkpoint blockade by anti-PD-L1 monoclonal antibody (αPD-L1) has achieved unprecedented clinical benefits in certain cancers
Feedback